Author: NTIDC-EmpireDD

Gilead’s New Capsid Inhibitor in Early Trials
Post

Gilead’s New Capsid Inhibitor in Early Trials

Gilead’s new capsid inhibitor GS-6207 has started its phase 1b trial with the potential for 3 month dosing. The capsid inhibitor is currently being dosed by a subcutaneous injection but Gilead is attempting to develop a oral formulation of the antiretroviral.

Infectious Disease Medicine
Project

Infectious Disease Medicine

Infectious Diseases physicians are highly trained specialists, having spent 4 years completing medical school training, 3 years completing an Internal Medicine Residency Training Program and a minimum of 2 years of sub-specialty fellowship training in Infectious Diseases Medicine.

Outpatient Surgery
Project

Outpatient Surgery

Cum sociis natoque penatibus et magnis dis parturient montesmus. Pro vel nibh et elit mollis commodo et nec augueique

Pediatric Clinic
Project

Pediatric Clinic

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec vestibulum erat at eros viverra vehicula. Ut ultrices aliquet lacus nec gravida. Pellentesque porttitor, augue nec lobortis tempor, neque tellus convallis nisl, in iaculis odio sapien at libero. Sed purus turpis, aliquam in lobortis ut, faucibus eu arcu. Etiam magna tellus, laoreet sit amet nisl a,...

North Texas Infectious Diseases